My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Merck & Co (NY:MRK)

119.20 -0.95 (-0.79%)

Streaming Delayed Price Updated: 9:33 AM EDT, Apr 14, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

1 Profitable Stock for Long-Term Investors and 2 Facing Challenges

Today 0:33 EDT

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi...

Via StockStory

The Science of Scale: An In-Depth Look at Regeneron Pharmaceuticals (REGN) in 2026

April 13, 2026

As of today, April 13, 2026, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) stands as a titan of the biotechnology sector, representing a rare blend of scientific purity and commercial dominance. In an...

Via Finterra

Ifinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer who Experienced Disease Progression on or After Platinum-Based Chemotherapy

April 13, 2026

From Daiichi Sankyo

Via Business Wire

Merck & Co. Inc. (NYSE:MRK) Offers a Durable Dividend Backed by Strong Earnings ↗

April 09, 2026

Via Chartmill

1 Momentum Stock on Our Buy List and 2 We Question

April 13, 2026

Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements...

Via StockStory

Which Dividend Pharma Stock Should a Value Investor Choose Today? ↗

April 12, 2026

Bristol Myers Squibb looks like a value buy, so long as its pipeline remains strong.

Via The Motley Fool

Topics Intellectual Property

Gilead Sciences Solidifies Oncology Future with $5 Billion Acquisition of ADC Innovator Tubulis

April 09, 2026

In a bold move to dominate the rapidly evolving cancer treatment landscape, Gilead Sciences (Nasdaq: GILD) announced on April 7, 2026, its acquisition of the German biotech firm Tubulis for a total...

Via MarketMinute

Topics Bonds

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Terns Therapeutics, Inc. (Nasdaq – TERN), Whitestone REIT (NYSE – WSR), Rallybio Corporation (Nasdaq – RLYB), Day One Biopharmaceuticals, Inc. (Nasdaq - DAWN)

April 09, 2026

From Brodsky & Smith LLC

Via GlobeNewswire

ImmunityBio (IBRX): From R&D Speculation to Record Commercial Revenue

April 09, 2026

Today's Date: April 9, 2026 Introduction In the high-stakes arena of biotechnology, few companies have undergone a transformation as dramatic as ImmunityBio, Inc. (NASDAQ: IBRX). Long viewed by Wall...

Via Finterra

Topics Economy World Trade

Why Terns Pharmaceuticals Stock Rocked the Market in March ↗

April 08, 2026

A large peer is snapping up the company in a premium-priced deal.

Via The Motley Fool

Topics Intellectual Property

Merck Begins Tender Offer to Acquire Terns Pharmaceuticals, Inc.

April 07, 2026

From Merck & Co., Inc.

Via Business Wire

You'll Never Guess Which Healthcare Stock Delivered the Best First-Quarter Performance in the S&P 500. ↗

April 07, 2026

Could this player be heading into a new era of growth?

Via The Motley Fool

Topics Artificial Intelligence Economy Stocks

Merck’s Oncology Empire Expands: Keytruda Secures Pivotal European Commission Approval for Recurrent Ovarian Cancer

April 02, 2026

BRUSSELS — In a major victory for one of the world’s leading pharmaceutical giants, the European Commission (EC) has officially granted marketing authorization for Merck & Co. (NYSE: MRK) blockbuster...

Via MarketMinute

Topics Intellectual Property

Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus), an Investigational Bispecific Tie2 Agonist/VEGF Inhibitor, for the Treatment of Neovascular Age-Related Macular Degeneration

April 02, 2026

From Merck & Co., Inc.

Via Business Wire

European Commission Approves KEYTRUDA® (pembrolizumab) Plus Paclitaxel ± Bevacizumab for the Treatment of Adults With PD-L1 (CPS ≥1) Platinum-Resistant Recurrent Ovarian Carcinoma Who Have Received One or Two Prior Systemic Treatment Regimens

April 02, 2026

From Merck & Co., Inc.

Via Business Wire

The New Blue-Chip: How Johnson & Johnson Refined Its Empire for a High-Growth Future

April 01, 2026

As we enter the second quarter of 2026, Johnson & Johnson (NYSE: JNJ) stands as a starkly different entity than the consumer-facing conglomerate that defined the 20th century. Having successfully shed...

Via Finterra

Topics Artificial Intelligence Earnings Economy

Merck to Hold First-Quarter 2026 Sales and Earnings Conference Call April 30

April 01, 2026

From Merck & Co., Inc.

Via Business Wire

Biotech Defies Gravity: Sarepta and Corcept Lead Midday Healthcare Rally Amidst Market Volatility

March 31, 2026

In a trading session characterized by sharp declines across the technology and industrial sectors, the healthcare industry emerged as a resilient fortress on March 31, 2026. While the broader S&P 500...

Via MarketMinute

Topics Economy Intellectual Property Stocks

Moderna 2.0: The mRNA Pioneer’s Pivot to Oncology and the Path to 2028 Profitability

March 31, 2026

As of March 31, 2026, Moderna Inc. (NASDAQ: MRNA) finds itself at a defining historical junction. After years of being defined by a single, world-altering product—its COVID-19 vaccine—the...

Via Finterra

Topics Initial Public Offering

Merck Just Made a Big Bet on a New Cancer Growth Engine ↗

March 31, 2026

Via MarketBeat

Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Demonstrated Significantly Greater LDL-C Reductions at Eight Weeks Compared to Guideline-Recommended Oral Non-Statin Therapies When Added to Background Statins

March 30, 2026

From Merck & Co., Inc.

Via Business Wire

This Top ETF Recently Added a Healthy Dose of These High-Yielding Dividend Stocks ↗

March 30, 2026

The Schwab U.S. Dividend Equity ETF is increasing its allocation to healthcare dividend stocks.

Via The Motley Fool

Topics ETFs Stocks

Positive Data from Phase 2 CADENCE Trial Provides Definitive Proof-of-Concept for WINREVAIR™ (sotatercept-csrk) in Adults With the Syndrome of Combined Post- and Precapillary Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction

March 29, 2026

From Merck & Co., Inc.

Via Business Wire

1 Reason Eli Lilly Stock Is Still a Buy ↗

March 28, 2026

Eli Lilly is much more than just a weight loss stock.

Via The Motley Fool

Topics Artificial Intelligence

2 Healthcare Stocks That Could Soar Over the Next 5 Years ↗

March 26, 2026

They could make important breakthroughs in their target markets.

Via The Motley Fool

MarketMinute: Corcept Therapeutics (CORT) Surges 19.66% on Surprise FDA Approval and Oncology Breakthrough

March 26, 2026

The biotechnology sector witnessed a seismic shift on March 26, 2026, as shares of Corcept Therapeutics (NASDAQ: CORT) surged 19.66% in heavy trading. The rally, which added nearly $1 billion to the...

Via MarketMinute

Topics Intellectual Property

ARM Makes Its Move While Wall Street Watches the Strait ↗

March 26, 2026

Via Chartmill

The Strategic Renaissance: Why 2026 is the Year of the Takeover Tailwind

March 25, 2026

As of March 25, 2026, the global financial markets are witnessing a seismic shift in corporate strategy, marking the definitive end of the "deal winter" that chilled boardrooms for much of the early...

Via MarketMinute

Topics Artificial Intelligence Economy

The $6.7 Billion Pivot: A Deep Dive into Terns Pharmaceuticals (TERN) and the Merck Acquisition

March 25, 2026

On this Wednesday, March 25, 2026, the biotechnology sector has been electrified by the announcement that Merck & Co. (NYSE: MRK) will acquire Terns Pharmaceuticals, Inc. (NASDAQ: TERN) in an all-cash...

Via Finterra

Topics Initial Public Offering Intellectual Property World Trade

Merck & Co. (MRK) 2026 Analysis: Navigating the Keytruda Cliff with Pipeline-Driven Resilience

March 25, 2026

As of March 25, 2026, Merck & Co., Inc. (NYSE: MRK) stands at a pivotal crossroads in its 135-year history. Known globally as a titan of oncology and vaccines, the Rahway, New Jersey-based...

Via Finterra

Topics Artificial Intelligence Economy Intellectual Property

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.